A bipartisan bill to require patent transparency in an effort to bring down the cost of prescription drugs has been introduced in the House of Representatives; the bill is a piece of companion legislation to one introduced in the Senate in March.
A bipartisan bill to require patent transparency in an effort to bring down the cost of prescription drugs has been introduced in the House of Representatives; the bill is a piece of companion legislation to one introduced in the Senate in March.
The Biologic Patent Transparency Act aims to end patenting practices that make it difficult for biosimilars to enter the market by increasing transparency in the prescription drug market and promoting competition. The act would require companies to publicly disclose the patents that protect their originator biologics, thus making it easier for competitors to evaluate and plan for the development of biosimilars.
If the transparency bill becomes law, it would codify the publication of FDA’s Purple Book as a single, searchable list, as well as require additional information:
In addition, it would limit the enforceability of late-filed patents by the biologic manufacturer when a biosimilar application has already been filed with the FDA, such as those used by AbbVie to protect its brand name adalimumab (Humira) from competition.
Biologic manufacturers often seek to protect their products by using dozens or hundreds of patents; even if some of the patents are later found to be invalid or unenforceable by the court or the Patent Trial and Appeal Board, expensive litigation can deter competitors from moving forward with developing biosimilars.
Representatives Abigail Spanberger, D-Virginia, and Tom Reed, R-New York, introduced the bill; they are both members of the bipartisan Problem Solvers Caucus, which includes a bicameral prescription drug task force that Spanberger chairs. In June, they both announced support for new principles to address rising prescription drug prices, including fighting for greater transparency, competition, and affordability.
“As the co-chair of the Diabetes Caucus, one of the things we noticed when conducting our recent insulin report was the myriad of patent abuses that prevented new biologics from coming to market. This bill goes a long way in addressing this critical issue,” said Reed in a statement. “As the father of a type 1 diabetic, I care about ensuring people with diabetes have access to fairly priced insulin, and I know this bill will help people across the United States to lower the cost of their prescription drugs by injecting competition into the market,” Reed added.
“Across Central Virginia, I hear story after story about how high prescription drug costs are crippling the financial security of working families, retirees, and those with chronic conditions. For many of our neighbors, expanded access to lifesaving generic alternatives like biosimilars would help lower costs and give them new peace of mind—but the current level of complexity in the patent system makes it impossible for new drugs to compete,” said Spanberger.
Senator Susan Collins, R-Maine, and Senator Tim Kaine, D-Virginia, introduced the Senate bill in March.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.